JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Pooled Analysis of the Prognostic Significance of Epidermal Growth Factor Receptor (EGFR) Mutational Status in Combination with Other Driver Genomic Alterations in Stage I Resected Invasive Lung Adenocarcinoma for Recurrence-Free Survival: A Population-Based Study

  • 0Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Annals of Surgical Oncology +

|

November 25, 2024

|

November 25, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Epidermal growth factor receptor (EGFR) mutations are significant predictors of recurrence-free survival (RFS) in stage I lung adenocarcinoma (LUAD). Combining EGFR mutations with other actionable mutations improves RFS estimation for personalized treatment strategies.

Area Of Science

  • Oncology
  • Genomics
  • Molecular Biology

Background

  • Prognostic significance of EGFR mutations in stage I invasive lung adenocarcinoma (LUAD) is debated.
  • Accurate staging and identification of actionable mutations are crucial for improving LUAD patient outcomes.

Purpose Of The Study

  • To investigate the prognostic value of EGFR mutations in stage I invasive LUAD.
  • To assess the association between EGFR mutations and recurrence-free survival (RFS).
  • To develop a predictive model for RFS using genomic data.

Main Methods

  • Analyzed driver mutations in 410 stage I invasive LUAD patients.
  • Performed survival analysis using Kaplan-Meier and Cox regression models.
  • Developed and validated genomic prediction models using machine learning algorithms (Random Survival Forest).

Main Results

  • EGFR mutations were found in 51.2% of patients and correlated with poor RFS (P=0.022).
  • EGFR mutations showed significant association with poor RFS in never-smokers, females, part-solid tumors, and stage IA subgroups.
  • A Random Survival Forest model demonstrated strong RFS estimation performance (C-index: 0.87 training, 0.74 validation).

Conclusions

  • EGFR mutations are reliable biomarkers for estimating RFS in stage I invasive LUAD.
  • Integrating EGFR mutations with other actionable mutations enhances individualized RFS prediction.
  • Findings support the use of EGFR mutation status for risk stratification and personalized treatment in early-stage LUAD.

Keywords: